Literature DB >> 35116373

Clinical analysis of patients with respiratory failure after esophageal cancer operation.

Jun Dong1, Guo-Dong Wang1, Hong-Zhi Wang1.   

Abstract

BACKGROUND: To explore the clinical profiles and outcomes of patients with acute respiratory failure (ARF) after esophagectomy.
METHODS: We retrospectively analyzed cases of patients who had been diagnosed with ARF after esophagectomy and compared survivors with non-survivors to explore the risks that may affect their outcomes.
RESULTS: In total, 62 patients were admitted to the intensive care unit (ICU) with ARF after esophagectomy between January 1, 2010, and December 31, 2017. Of these patients, 69.4% needed mechanical ventilation, with an average time on the ventilator of 304 hours (304.33±374.37 hours). The average length of stay in the ICU and in the hospital were 14 days (14.48±17.64 days) and 50 days (50.15±37.28 days), respectively. Mortality in the ICU and 90 days after the operation was 6.5% and 16.1%, respectively. Compared with the survivors, the 90-day post-operative non-survivors had a poorer N stage in the TNM classification system. The causes of ARF included anastomotic leakage, pneumonia, vocal cord paralysis, sputum plugging, pulmonary embolism (PE), and acute respiratory distress syndrome (ARDS). ARF induced by different factors occurred at different times and had different outcomes. The three most common reasons for mortality in the ICU were ARDS (33.33%), anastomotic leakage (11.76%), and pneumonia (10%). The three most common reasons for mortality in the 90-day post-operative period were pneumonia (40%), anastomotic leakage (23.53%), and ARDS and acute exacerbations of chronic obstructive pulmonary disease (AECOPD) (33.33%).
CONCLUSIONS: Anastomotic leakage, pneumonia, ARDS, and AECOPD were the main causes of death in ARF patients after esophagectomy. We found that the N stage in the TNM classification system may affect 90-day post-operative mortality in these patients. 2021 Translational Cancer Research. All rights reserved.

Entities:  

Keywords:  Acute respiratory failure (ARF); TNM stage; anastomotic leakage; esophagectomy

Year:  2021        PMID: 35116373      PMCID: PMC8799240          DOI: 10.21037/tcr-21-1505

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


Introduction

Esophageal cancer is the ninth most common cancer worldwide (1). At the same time, it is the sixth leading cause of cancer-related mortality worldwide because of its high malignant potential and poor prognosis (2). For most patients without distant metastases, esophagectomy is still the mainstay of cancer treatment with or without chemoradiotherapy (3). Surgical resection of the esophagus offers curative potential, but the procedure is technically difficult. This highly invasive procedure is often followed by several serious postoperative complications, especially acute respiratory failure (ARF). ARF is the main cause of mortality in these post-operative patients (4). We analyzed 62 cases of patients who had ARF complications after esophagectomy to investigate the causes of ARF and the factors that influence survival and to provide evidence for precautions that could be taken to avoid respiratory failure after esophagectomy. We present the following article in accordance with the STROBE reporting checklist (available at https://dx.doi.org/10.21037/tcr-21-1505).

Methods

Patients

From January 1, 2010, to December 31, 2017, patients who had undergone esophagectomy for esophageal cancer at the Peking University Cancer Hospital were retrospectively screened. Patients admitted to the intensive care unit (ICU) suffering from ARF after esophagectomy were included in our study. ARF is defined as an inadequate exchange of oxygen and carbon dioxide. It is diagnosed when the exchange does not meet metabolic needs, leading to hypoxemia with or without hypercapnia. An arterial blood gas measurement provides the basis of the diagnosis; when the partial pressure of oxygen (PaO2) falls below 60 mmHg and/or the partial pressure of carbon dioxide exceeds 50 mmHg at sea level [fraction of inspired oxygen (FIO2) of 0.21], gas exchange is clearly inadequate (5). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by Ethics Committee of Peking University Cancer Hospital & Institute and individual consent for this retrospective analysis was waived. Patient variables, including demography, the TNM stage of their esophageal cancer, underlying diseases, and biomarkers, were collected according to historical electronic medical records. We also collected their operation details, including the time of the operation, fluid balance, and the time of one-lung ventilation. The cause of ARF, including anastomotic leakage, pneumonia, vocal codes paralysis, sputum plugging, pulmonary embolism, acute respiratory distress syndrome, acute exacerbations of chronic obstructive pulmonary disease, delay of recovery, atelectasis, Guillain-Barre Syndrome, phrenic nerve injury, acute heart failure were collected. Pneumonia was defined in the 2005 document as the presence of “new lung infiltrate plus clinical evidence that the infiltrate is of an infectious origin, which include the new onset of fever, purulent sputum, leukocytosis, and decline in oxygenation (6). The vocal codes paralysis was defined as the patient had difficulty in phonation and breathing. Laryngoscope or fiberoptic bronchoscope showed bilateral vocal cords and was placed in the midline with poor movement. The ARDS was according to the Berlin definition of ARDS (7). We also collected the APACHE II score on admission to the ICU, the time of the onset of ARF after the operation, the causes of ARF, and mortality in the ICU and 90 days after the operation.

Statistical methods

Data were analyzed using IBM’s SPSS, version 20. Qualitative variables were expressed as a number and percentage and were compared using the chi-square test. In addition, quantitative variables were expressed as mean ± standard deviation and were compared using the Student’s t-test. The difference between variables was considered statistically significant when the P value was ≤0.05.

Results

From January 1, 2010, to December 31, 2017, 1,872 patients who underwent esophagectomy for the treatment of esophageal cancer at the Peking University Cancer Hospital were screened retrospectively. Of these, 62 patients admitted to the ICU because of ARF after esophagectomy were included in our study. In our study, patients had a mean age of 63 years (63.35±7.55 years), and 12.9% (8/62) were female. Overall, 69.4% (43/62) of the patients needed mechanical ventilation, the average time on the ventilator was 304 hours (304.33±374.37 hours), the average length of stay in the ICU was 14 days (14.48±17.64 days), mortality in the ICU was 6.5% (4/62), and the average length of stay in the hospital was 50 days (50.15±37.28 days). Ninety-day mortality was 16.1 % (10/62). The causes of ARF in these 62 patients are listed in below. Anastomotic leakage was the primary cause of mortality both in the ICU and 90 days after the operation.
Table 1

Reasons to ARF after esophagectomy

CauseCasesMortality in ICUMortality within 90 days
Anastomotic leakage1711.76% (n=2)23.53% (n=4)
Pneumonia910.00% (n=1)40.00% (n=4)
Vocal cords paralysis70.00%0.00%
Sputum plugging70.00%0.00%
PE40.00%0.00%
ARDS333.33% (n=1)33.33% (n=1)
AECOPD30.00%33.33% (n=1)
Delay of recovery30.00%0.00%
Atelectasis30.00%0.00%
GB Syndrome20.00%0.00%
Phrenic nerve injury20.00%0.00%
AHF20.00%0.00%
Total626.45% (n=4)16.13% (n=10)

ARF, acute respiratory failure; PE, Pulmonary embolism; ARDS, acute respiratory distress syndrome; AECOPD, acute exacerbations of chronic obstructive pulmonary disease; GB Syndrome, Guillain-Barre Syndrome; AHF, acute heart failure.

ARF, acute respiratory failure; PE, Pulmonary embolism; ARDS, acute respiratory distress syndrome; AECOPD, acute exacerbations of chronic obstructive pulmonary disease; GB Syndrome, Guillain-Barre Syndrome; AHF, acute heart failure. The time of occurrence of ARF varied from within 24 hours to more than 15 days after the operation. Within 24 hours, the main causes of ARF were vocal cord paralysis (40%, 6/15) and delayed recovery from anesthesia (20%, 3/15). As time progressed, the rate of anastomotic leakage increased; it was at nearly 60% (4/7) when ARF occurred more than 15 days after the operation ().
Figure 1

ARF time distribution. ARF, acute respiratory failure; PE, pulmonary embolism; ARDS, acute respiratory distress syndrome; AECOPD, acute exacerbations of chronic obstructive pulmonary disease; AHF, acute heart failure.

ARF time distribution. ARF, acute respiratory failure; PE, pulmonary embolism; ARDS, acute respiratory distress syndrome; AECOPD, acute exacerbations of chronic obstructive pulmonary disease; AHF, acute heart failure. We also analyzed factors such as the TNM stage of esophageal cancer, underlying diseases, and biomarkers in these ARF patients to evaluate if they affected mortality. We found that the lymph node stage (L) might affect the 90-day mortality. Apart from this, there were no other factors that showed a statistically significant difference between the survivors and non-survivors ().
Table 2

Differences between survivors with non-survivors before operation

CharacteristicMortality in ICU90-day mortality
Non-survival (n=4)Survival (n=58)P valueNon-survival (n=10)Survival (n=52)P value
Age (year)61.50±6.1963.48±7.660.61563±5.1463.42±7.960.873
Gender0.4330.382
   Male75% (n=3)87.9% (n=51)80% (n=8)88.5% (n=46)
   Female25% (n=1)12.1% (n=7)20% (n=2)11.5% (n=6)
BMI (kg/m2)22.98±2.8023.75±3.790.69222.62±2.7323.90±3.870.323
TNM stage
   T0.6440.839
    003.4% (n=2)03.8% (n=2)
    1019.0% (n=11)30% (n=3)15.4% (n=8)
    250% (n=2)20.7% (n=12)20% (n=2)23.1% (n=12)
    350% (n=2)48.3% (n=28)40% (n=4)50% (n=26)
    406.9% (n=4)10% (n=1)5.8% (n=3)
    x01.7% (n=1)01.9% (n=1)
   N0.103
    025% (n=1)70.7% (n=41)30% (n=3)75% (n=39)
    150% (n=2)15.5% (n=9)30% (n=3)15.4% (n=8)
    206.9% (n=4)07.7% (n=4)
    325% (n=1)6.9% (n=4)40% (n=4)1.9% (n=1)
Pathology1.0000.317
   Squamous cell carcinomas100% (n=4)93.1% (n=54)90% (n=9)94.2% (n=49)
   Adenocarcinoma03.4% (n=2)03.8% (n=2)
   small cell carcinoma01.7% (n=1)01.9% (n=1)
   Signet ring cell carcinoma01.7% (n=1)10% (n=1)0
Smoking history0.7280.507
   Yes75% (n=3)74.1% (n=43)70% (n=7)75% (n=39)
   No25% (n=1)25.9% (n=15)30% (n=3)25% (n=13)
Drinking history0.4110.279
   Yes75% (n=3)55.2% (n=32)70% (n=7)53.8% (n=28)
   No25% (n=1)44.8% (n=26)30% (n=3)46.2% (n=24)
Chemotherapy before operation0.5330.634
   Yes50% (n=2)39.7% (n=23)40% (n=4)40.4% (n=21)
   No50% (n=2)60.3% (n=35)60% (n=6)59.6% (n=31)
Hypertension0.5530.229
   Yes25% (n=1)36.2% (n=21)20% (n=2)38.5% (n=20)
   No75% (n=3)63.8% (n=37)80% (n=8)61.5% (n=32)
DM0.3420.246
   Yes25% (n=1)8.6% (n=5)20% (n=2)7.7% (n=4)
   No75% (n=3)91.4% (n=53)80% (n=8)92.3% (n=48)
CHD0.8160.584
   Yes05.2% (n=3)05.8% (n=3)
   No100% (n=4)94.8% (n=55)100% (n=10)94.2% (n=49)
Biomarkers before operation
   WBC (×109/L)5.85±1.826.67±2.660.5486.00±1.336.74±2.790.421
   HGB (g/L)142.75±23.81138.62±18.350.670141.2±27.80138.44±16.530.670
   PLT (×109/L)223.5±79.66209.79±62.960.680201±73.70212.54±61.940.603
   AST (IU/L)20.25±5.1221.83±6.010.61120.0±3.5622.06±6.250.319
   ALT (IU/L)17.00±2.0016.90±9.280.98216.50±5.3816.98±9.550.878
   TBIL (µmol/L)13.40±6.2116.33±20.000.77329.53±45.3913.40±4.690.290
   DBIL (µmol/L)4.78±2.126.11±18.710.88818.04±43.593.57±1.220.321
   TP (g/L)73.48±4.2970.96±7.060.48771.13±8.6671.12±6.610.999
   ALB (g/L)47.28±3.5044.44±5.490.31543.85±8.8544.78±4.550.622
   Cr (µmol/L)71.00±15.8574.91±20.220.70764.67±26.4576.58±18.060.083
   BUN (mmol/L)5.34±1.066.87±7.790.69911.57±18.485.85±1.570.353
Lung function
   Ventilation function impaired0.1610.109
    Yes33.3% (n=1)76.5% (n=39)50% (n=4)78.3% (n=36)
    No66.7% (n=2)23.5% (n=12)50% (n=4)21.7% (n=10)
   Diffusion function impaired0.5340.17
    Yes019.6% (n=10)100% (n=8)78.3% (n=36)
    No100% (n=3)80.4% (n=41)021.7% (n=10)
   Echocardiography
    LVEF61.00±1.4165.93±5.540.22064.67±4.8465.88±5.650.622
    E/A ≥1100% (n=1)35.7% (n=15)0.37260% (n=3)34.2% (n=13)0.260
    E/A <1064.3% (n=27)40.0% (n=2)65.8% (n=25)

DM, diabetes mellitus; CHD, coronary heart disease; LVEF, left ventricular ejection fraction; E/A, E wave A wave ratio.

DM, diabetes mellitus; CHD, coronary heart disease; LVEF, left ventricular ejection fraction; E/A, E wave A wave ratio. There were no significant differences between the ARF patients during the operation (). Understandably, the non-survivors were more seriously ill than the survivors on admission to the ICU ().
Table 3

Differences between survivors with non-survivors during operation

Operation characteristicMortality in ICU90-day mortality
Non-survivalSurvivalP valueNon-survivalsurvivalP value
Operation1.0001.000
   McKeown75% (n=3)60.3% (n=35)60% (n=6)61.5% (n=32)
   Ivor-Lewis operation25% (n=1)36.2% (n=21)40% (n=4)34.6% (n=18)
   Sweet 03.4% (n=2)03.8% (n=2)
Operation time (min)312.50±132.00342.84±100.940.570343.00±134.42340.48±96.380.944
Fluid
   Colloidal fluid (mL)1,125.00±250.001,022.41±380.690.5991,200.00±483.05996.15±344.120.114
   Crystalloid fluid (mL)1,925.00±722.842,163.79±579.080.4352,095.00±506.872,158.65±603.070.756
   Fluid balance2,280.00±485.042,576.72±615.890.3512,637.00±744.552,542.31±587.320.656
One-lung ventilation time (min)100.00±32.78128.44±55.660.618115.00±12.91129.31±58.430.268
Blood loss (mL)245.00±136.99201.72±142.950.560248.00±220.19196.15±122.810.294
Table 4

Patients severity

Patients severityMortality in ICU90-day mortality
Non-survivalSurvivalP valueNon-survivalSurvivalP value
Lactic acid clearance rate (%)38.58±40.6926.20±39.370.54533.89±29.52225.68±40.830.463
Organ dysfunction0.0110.002
   Yes100% (n=4)29.3% (n=17)80% (n=8)25% (n=13)
   No070.7% (n=41)20% (n=2)75% (n=39)
APACHE II score20.75±7.5014.72±6.270.07119.60±8.6214.25±5.660.015

Discussion

Esophagectomy is a highly invasive procedure with several serious post-operative complications, including pneumonia, anastomotic leakage, and recurrent laryngeal nerve paralysis, which may result in ARF or even multi-organ failure (8,9). In our study, the top three causes of ARF were anastomotic leakage, pneumonia, vocal cord paralysis, and sputum plugging. Anastomotic leakage and pneumonia were not only the main causes of ARF but also of mortality in the ICU and 90 days after the operation. As is well understood, the different causes of ARF significantly influence long-term survival. In this respect, ARF patients who developed anastomotic leakage and pneumonia had a significantly higher risk of a poor outcome, while ARF patients with vocal cord paralysis and sputum plugging were more likely to have a good outcome. This is consistent with previous studies (10). The results in show that the causes of ARF within 24 hours of the operation mainly consisted of delayed recovery from anesthesia, vocal cord paralysis, and sputum plugging. The reason that delayed recovery from anesthesia is a cause of ARF is clear. To counter this, we can use an antagonist to the anesthetic until the patient is awake. In terms of vocal cord paralysis, this is caused by the recurrent laryngeal nerve (RLN) being injured during esophagectomy, especially McKeown esophagectomy. To avoid this, surgeons should take extra care or use a special trachea cannula that can monitor the RLN using an electrode. The reason that sputum plugging is considered a cause of ARF is because these patients are too weak to clear sputum or the cough/gag reflex is absent. Timing of the onset of ARF varied from less than 24 hours to 4 days after the operation. Thus, we should constantly monitor the airway, help patients with breathing exercises, and facilitate the clearing of sputum. If necessary, we should use a fiber tracheoscope to aspirate the sputum. Delayed recovery from anesthesia, vocal cord paralysis, and sputum plugging cause ARF by obstructing the upper airway. To treat this, we need to open the airway immediately, including the oropharyngeal airway, suction the sputum, and apply tracheal intubation. Patients with delayed recovery from anesthesia, vocal cord paralysis, and sputum plugging that receive these treatments always have a good outcome without any remaining sequelae. In the case of patients who suffer from ARF several days after the operation, we should consider whether there are likely to be serious complications, such as thorax infection, pneumonia, and pulmonary thromboembolism (PE). Thorax infection, which can be caused by anastomotic leakage, is of particular concern. Anastomotic leakage can be diagnosed using water-soluble contrast swallow, a computed tomography scan, gastroscopy, or bronchoscopy. It is difficult and expensive to cure thorax infections caused by anastomotic leakage. ARF patients with anastomotic leakage had higher mortality than other patients. To treat these patients, apart from using antibiotics, sufficient drainage, and providing nutritional support, surgical intervention may be necessary. In addition, PE needs to be considered. Computer tomography pulmonary angiography is helpful in diagnosing PE. To prevent it, we can administer heparin or low molecular weight heparin in patients with a low risk of bleeding. In this study, we compared the differences in the patient’s demography, comorbidity, and organ functions, as well as other factors, between the survivors and non-survivors. We found only the N stage in the TNM classification to be statistically significant in relation to 90-day mortality between the two groups. Previous studies achieved similar results. The number of regional lymph nodes containing metastases is the most important prognostic factor in patients undergoing resection for esophageal cancer (11). We could not demonstrate any character association between the survivors and non-survivors perioperation, indicating that preoperative identification of patients at high ARF risk is difficult. Sachdev et al. noted that there are some ARF risk factors after almost all kinds of surgery. But in terms of esophagectomy, they demonstrated that the evidence, which were of poor quality or were conflicted, were hard to determine whether the factors increase the risk or whether the laboratory tests predicting risk (12). Finally, in our study, the total number of cases of ARF after esophagectomy was about 3.3% (62/1,872). This is much lower than in previous studies, which had figures of 33–38% (13,14). The possible reason for this is that, in our study, we enrolled ARF patients who had been transferred to the ICU, but all were ARF patients. Some ARF patients, especially those with mild symptoms, remained on the wards. Several limitations should be mentioned. First, this study was a retrospective study. A prospective study with a control group consisting of patients without ARF may be more useful. Second, some data were missing, especially data regarding ultrasound cardiogram and lung function. Third, the sample size in our study was small, thus increasing the risk of a type 2 error due to a lack of statistical power. Larger studies are needed to address the challenging issues arising during the treatment of ARF patients after esophagectomy.

Conclusions

ARF is a severe complication after esophagectomy. But ARF caused by different institutions will have different outcomes. Anastomotic leakage, pneumonia, ARDS and AECOPD were the main causes of death in ARF patients after esophagectomy. We found the N stage of the TNM classification to be statistically significant in relation to the difference between survivors and non-survivors.
  14 in total

1.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

2.  Efficacy of intraoperative, single-bolus corticosteroid administration to prevent postoperative acute respiratory failure after oesophageal cancer surgery.

Authors:  Seong Yong Park; Hyun-Sung Lee; Hee-Jin Jang; Jungnam Joo; Jae Ill Zo
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-06-28

3.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.

Authors:  J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

4.  The prognostic importance of the number of dissected lymph nodes after induction chemoradiotherapy for esophageal cancer.

Authors:  Jennifer M Hanna; Loretta Erhunmwunsee; Mark Berry; Thomas D'Amico; Mark Onaitis
Journal:  Ann Thorac Surg       Date:  2014-11-20       Impact factor: 4.330

5.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 6.  Postoperative pulmonary complications: pneumonia and acute respiratory failure.

Authors:  Gaurav Sachdev; Lena M Napolitano
Journal:  Surg Clin North Am       Date:  2012-04       Impact factor: 2.741

7.  Postoperative pulmonary complications are associated with worse short- and long-term outcomes after extended esophagectomy.

Authors:  Shoichi Kinugasa; Mitsuo Tachibana; Hiroshi Yoshimura; Shuhei Ueda; Toshiyuki Fujii; Dipok Kumar Dhar; Takeru Nakamoto; Naofumi Nagasue
Journal:  J Surg Oncol       Date:  2004-11-01       Impact factor: 3.454

Review 8.  Oesophageal cancer.

Authors:  Jesper Lagergren; Elizabeth Smyth; David Cunningham; Pernilla Lagergren
Journal:  Lancet       Date:  2017-06-22       Impact factor: 79.321

9.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

Review 10.  Meta-analysis of the impact of postoperative complications on survival after oesophagectomy for cancer.

Authors:  E Booka; H Takeuchi; K Suda; K Fukuda; R Nakamura; N Wada; H Kawakubo; Y Kitagawa
Journal:  BJS Open       Date:  2018-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.